These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24739994)

  • 41. Corneal and Tear Film Changes After Botulinum Toxin-A in Blepharospasm or Hemifacial Spasm.
    Gunes A; Demirci S; Koyuncuoglu HR; Tok L; Tok O
    Cornea; 2015 Aug; 34(8):906-10. PubMed ID: 26075455
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Routine use of Xeomin in patients previously treated with Botox: long term results.
    Dressler D
    Eur J Neurol; 2009 Dec; 16 Suppl 2():2-5. PubMed ID: 20002739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm.
    Rieder CR; Schestatsky P; Socal MP; Monte TL; Fricke D; Costa J; Picon PD
    Clin Neuropharmacol; 2007; 30(1):39-42. PubMed ID: 17272968
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The combined treatment with orbital and pretarsal botulinum toxin injections in the management of poorly responsive blepharospasm.
    Esposito M; Fasano A; Crisci C; Dubbioso R; Iodice R; Santoro L
    Neurol Sci; 2014 Mar; 35(3):397-400. PubMed ID: 23949734
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
    Park DI; Shin HM; Lee SY; Lew H
    Acta Ophthalmol; 2013 Mar; 91(2):e108-12. PubMed ID: 23425111
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm.
    Ho RW; Fang PC; Chao TL; Chien CC; Kuo MT
    Sci Rep; 2018 May; 8(1):8367. PubMed ID: 29849166
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study.
    Kongsengdao S; Kritalukkul S
    J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S48-54. PubMed ID: 22619887
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm.
    Yoon JS; Kim JC; Lee SY
    Korean J Ophthalmol; 2009 Sep; 23(3):137-41. PubMed ID: 19794937
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum calcium, magnesium, phosphorus, and vitamin D in benign essential blepharospasm.
    Serefoglu Cabuk K; Tunc U; Ozturk Karabulut G; Fazil K; Karaagac Gunaydin Z; Asik Nacaroglu S; Taskapili M
    Graefes Arch Clin Exp Ophthalmol; 2020 Jun; 258(6):1293-1297. PubMed ID: 32236706
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.
    Frevert J
    Drugs R D; 2010; 10(2):67-73. PubMed ID: 20698714
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm.
    Bentivoglio AR; Fasano A; Ialongo T; Soleti F; Lo Fermo S; Albanese A
    Eur J Neurol; 2009 Mar; 16(3):392-8. PubMed ID: 19364366
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of blepharospasm with botulinum neurotoxin type A: long-term results.
    Calace P; Cortese G; Piscopo R; Della Volpe G; Gagliardi V; Magli A; De Berardinis T
    Eur J Ophthalmol; 2003 May; 13(4):331-6. PubMed ID: 12872788
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)).
    Dressler D; Tacik P; Adib Saberi F
    J Neural Transm (Vienna); 2014 Jan; 121(1):29-31. PubMed ID: 23913131
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemodenervation for the Treatment of Facial Dystonia: A Report by the American Academy of Ophthalmology.
    Bilyk JR; Yen MT; Bradley EA; Wladis EJ; Mawn LA
    Ophthalmology; 2018 Sep; 125(9):1459-1467. PubMed ID: 29653859
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A prospective, multicentre, randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA to treat plantarflexor/invertor overactivity after stroke.
    Dunne JW; Gracies JM; Hayes M; Zeman B; Singer BJ;
    Clin Rehabil; 2012 Sep; 26(9):787-97. PubMed ID: 22308557
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized, placebo-controlled, crossover clinical trial of super blue-green algae in patients with essential blepharospasm or Meige syndrome.
    Vitale S; Miller NR; Mejico LJ; Perry JD; Medura M; Freitag SK; Girkin C
    Am J Ophthalmol; 2004 Jul; 138(1):18-32. PubMed ID: 15234278
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Riolan's muscle: action and indications for botulinum toxin injection.
    Mackie IA
    Eye (Lond); 2000 Jun; 14 ( Pt 3A)():347-52. PubMed ID: 11026998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.